Summary
Good management of patients with T-lymphoblastic leukemia requires identifying those at higher risk of morbidity and mortality. End-induction minimal residual disease appears to be a useful tool for predicting outcome and managing treatment, while classifying patients according to the presence of early thymic precursor immunophenotype does not improve risk assessment.
- children
- T-cell acute lymphoblastic leukemia
- end-induction minimal residual disease
- early thymic precursor immunophenotype
- AALL0434
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma [NCT00408005]
- © 2014 SAGE Publications
Tools
AALL0434 Treatment Therapy Has Excellent Outcomes in Children With T-ALL
Permalink:
Table of contents
Cited By...
- No citing articles found.